A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the body's immune response when vaccines are given
alone versus when vaccines are given along with the study drug called ixekizumab. The
vaccines protect against pneumonia and tetanus. This study will last about 6 weeks with
follow-up at 12 weeks.